文拉法辛缓释片与帕罗西汀治疗首发抑郁症对照研究  

Clinical study of Pa Rossi Dean and Vin Rafa Sin sustained re-lease tablets in the treatment of first-episode depression

作　　者：王建刚 王振英[2] 李全会[2] 

机构地区：[1]漯河市精神病医院,河南 ·漯河462300 [2]新乡医学院第二附属医院,河南 ·新乡453002

出　　处：《临床心身疾病杂志》2015年第5期60-61,66,共3页Journal of Clinical Psychosomatic Diseases

摘　　要：目的：探讨文拉法辛缓释剂与帕罗西汀治疗首发抑郁症患者的临床疗效和安全性。方法将60例抑郁症患者随机分为两组，每组30例，观察组口服文拉法辛缓释剂治疗，对照组口服帕罗西汀治疗，观察6周。于治疗前后采用汉密顿抑郁量表评定临床疗效，社会功能缺陷量表评定社会功能状况，副反应量表评定不良反应。结果治疗第2周末起两组汉密顿抑郁量表、社会功能缺陷量表评分均较治疗前有显著下降（P＜0．05或0．01），治疗各时点两组评分比较差异均无显著性（P ＞0．05）；治疗6周末，观察组显效率为80．0％、总有效率为90．0％，对照组分别为70．0％、80．0％，两组比较差异无显著性（P＞0．05）。两组不良反应均较轻微，发生率比较差异无显著性（P＞0．05）。结论文拉法辛缓释剂与帕罗西汀治疗首发抑郁症起效快，疗效显著，安全性高，且能显著提高患者的社会功能与生活质量。Objective To explore the efficacy and safety of venlafaxine hydrochloride sustained‐release tab‐lets （VHSRT ） and paroxetine in the treatment of first‐episode depression （FED） .Methods Sixty FED patients were randomly assigned to two groups of 30 ones each ,observation group took orally V HSRT and control did paroxetine for 6 weeks . Efficacies were assessed with the Hamilton Depression Scale （HAMD） ,social functions with the Social Disability Screening Schedule （SDSS） ,and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results Since the end of the 2nd week the HAMD and SDSS scores of both groups lowered more significantly compared with pretreatment （ P 〈 0 .05 or 0 .01） ,there were no significant group differences at all time‐points （P〉 0 .05） ;at the end of the 6th week obvious and total effective rate were respectively 80 .0% and 90 .0% in observation and 70 .0% and 80 .0%in control group ,which showed no significant differences （P 〉 0 .05） .Adverse reactions of both groups were mild ,their incidences had no significant group differences （P〉 0 .05） .Conclusion Both V HSRT and paroxetine take effect rapidly in the treatment of first‐episode depression ,have higher safety and better compliance ,and could notably improve patients＇social function and quality of life .

关 键 词：首发抑郁症 文拉法辛缓释片 帕罗西汀 汉密顿抑郁量表 社会功能缺陷量表 副反应量表 

分 类 号：R749.4[医药卫生—神经病学与精神病学]